» Articles » PMID: 38073734

Silent Myocardial Ischemia Revisited, Another Silent Killer, Emphasis on the Diagnostic Value of Stress Echocardiography with Focused Update and Review

Overview
Journal Adv Biomed Res
Date 2023 Dec 11
PMID 38073734
Authors
Affiliations
Soon will be listed here.
Abstract

Silent myocardial ischemia (SMI) is a relatively common phenomenon in patients with coronary artery disease (CAD). The original description of SMI dates back to the 1970s. We performed an extensive search of the literature starting from 2000, using MEDLINE or PubMed, and 676 documents were analyzed, and only 45 articles found suitable for the study were selected. Data regarding the prevalence and risk factors of SMI were discussed, along with the different mechanistic processes behind it; also, methods for screening and diagnosis are exposed, namely electrocardiographic stress test, stress echocardiography, and single-photon emission computed tomography (SPECT). The silent nature of the condition presumes that patients are diagnosed at a more advanced stage, and screening high-risk patients for early management is essential. Education of patients is necessary, and medical management along with cardiac rehabilitation is valid for mild cases, whereas patients with moderate-to-severe myocardial ischemia might require a more invasive approach. SMI is relatively common, diagnostic approach offers data regarding the presence of ischemia along with its anatomic extent, providing important prognostic value. Given its silent and critical nature, future directions for better screening and management must be searched and implemented extensively.

Citing Articles

Coronary health index based on immunoglobulin light chains to assess coronary heart disease risk with machine learning: a diagnostic trial.

Ren W, Zhang Z, Wang Y, Wang J, Li L, Shi L J Transl Med. 2025; 23(1):22.

PMID: 39762962 PMC: 11706159. DOI: 10.1186/s12967-024-06043-4.


Left Ventricular Thrombus With Silent Myocardial Infarction in a Patient With Factor V Leiden Mutation and High Factor VIII Levels: A Case Report.

Zahid A, Shariff M, Huggett R Cureus. 2025; 16(12):e74944.

PMID: 39744300 PMC: 11693404. DOI: 10.7759/cureus.74944.


Silent Myocardial Ischemia: From Pathophysiology to Diagnosis and Treatment.

Theofilis P, Antonopoulos A, Sagris M, Papanikolaou A, Oikonomou E, Tsioufis K Biomedicines. 2024; 12(2).

PMID: 38397860 PMC: 10886642. DOI: 10.3390/biomedicines12020259.

References
1.
Kumar G, Lal M, Singh G, Naik D . Correlation of Serum Nt-Pro Bnp Levels and Myocardial Performance Index in Asymptomatic Type 2 Diabetics for Assessment of Myocardial Ischaemia. J Assoc Physicians India. 2022; 70(4):11-12. View

2.
Wimmer N, Scirica B, Stone P . The clinical significance of continuous ECG (ambulatory ECG or Holter) monitoring of the ST-segment to evaluate ischemia: a review. Prog Cardiovasc Dis. 2013; 56(2):195-202. PMC: 4349575. DOI: 10.1016/j.pcad.2013.07.001. View

3.
Arenja N, Mueller C, Ehl N, Brinkert M, Roost K, Reichlin T . Prevalence, extent, and independent predictors of silent myocardial infarction. Am J Med. 2013; 126(6):515-22. DOI: 10.1016/j.amjmed.2012.11.028. View

4.
Zellweger M, Maraun M, Osterhues H, Keller U, Muller-Brand J, Jeger R . Progression to overt or silent CAD in asymptomatic patients with diabetes mellitus at high coronary risk: main findings of the prospective multicenter BARDOT trial with a pilot randomized treatment substudy. JACC Cardiovasc Imaging. 2014; 7(10):1001-10. DOI: 10.1016/j.jcmg.2014.07.010. View

5.
Ryden L, Mellbin L . Joint ESC/EASD guidelines on diabetes, where are we now and where should we go?. Curr Vasc Pharmacol. 2012; 10(6):690-2. DOI: 10.2174/157016112803520891. View